0001567619-18-002811.txt : 20180918
0001567619-18-002811.hdr.sgml : 20180918
20180918160901
ACCESSION NUMBER: 0001567619-18-002811
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180914
FILED AS OF DATE: 20180918
DATE AS OF CHANGE: 20180918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abdun-Nabi Daniel
CENTRAL INDEX KEY: 0001380187
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 181075777
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DRIVE
STREET 2: SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc1.xml
FORM 4
X0306
4
2018-09-14
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380187
Abdun-Nabi Daniel
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG
MD
20879
1
1
0
0
CEO
Common Stock
2018-09-14
4
M
0
28220
13.38
A
194787
D
Common Stock
2018-09-14
4
S
0
28220
65.00
D
166567
D
Common Stock
2018-09-17
4
M
0
1319
13.38
A
167886
D
Common Stock
2018-09-17
4
S
0
1319
65.00
D
166567
D
Common Stock
1936
I
By Son
Stock Option (Right to Buy)
13.38
2018-09-14
4
M
0
28220
0.00
A
2020-03-11
Common Stock
28220
1319
D
Stock Option (Right to Buy)
13.38
2018-09-17
4
M
0
1319
0.0
A
2020-03-11
Common Stock
1319
0
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Consists of an option granted under the company's stock incentive plan as amended and restated.
The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant.
/s/ S. Scott Lieberman, Attorney-in-fact
2018-09-18